交银国际发报告指，蔚来汽车(09866.HK)旗下乐道L90定价积极，整车起售价为26.58万元人民币，即使 是顶配的Ultra版亦未突破30万元人民币。综合定价策略及渠道反馈，该行预计集团每月稳定销量将超 市场预期的5000台。同时认为，蔚来的边际改善及降本效果将为市场焦点。虽股价已较低位反弹50%， 但集团2025年市销率仅为0.85倍，边际改善股价或迎来持续反弹机会。维持"买入"评级。 交银国际：蔚来L90定价积极 料每月稳定销量将超5000台 ...

智通财经APP获悉，交银国际发布研报称，维持蔚来-SW(09866)"买入"评级，边际改善股价迎来短期反 弹机会。该行认为未来市场焦点或在于蔚来的边际改善(特别是销量回升)的可持续性，同时降本效果能 否达到市场的预期。虽然股价已较低位反弹50%，但目前蔚来2025年市销率仅为0.85倍，依然较新势力 同行估值的1-2倍为低，边际改善股价或迎来持续反弹机会。 报告中称，乐道L90正式登陆市场，整车起售价为26.58万元(Pro版;人民币，下同)，而Max与Ultra版则 分别为27.98万元与29.98万元;七座车型在此基础上加价6000元(即27.18万元起)。BaaS(电池租赁)方案的 起步价为17.98万元(Pro版)，Max与Ultra版分别是19.38万元及21.38万元，七座版BaaS方案则从18.58万 元起售。相较于7月10日公布的预售价(整车购买27.99万元起，BaaS方案19.39万元起)，正式售价降低了 约1.41万元。在权益方面，新车全系标配85kWh电池、L2级别智能驾驶辅助系统以及Orin-X芯片等高端 配置，并推出2000元预订金抵扣5000元购车款及5000元选装基金的优惠，复 ...

Group 1 - The report from CMB International maintains a "Buy" rating for NIO-SW (09866), indicating a potential short-term rebound in stock price due to marginal improvements, particularly in sales recovery [1] - Despite a 50% rebound from lower levels, NIO's price-to-sales ratio for 2025 is only 0.85 times, which is still lower than the 1-2 times valuation of its peers in the new energy vehicle sector, suggesting further upside potential for the stock [1] Group 2 - The launch of the Lido L90 model has a starting price of 265,800 RMB for the Pro version, with the Max and Ultra versions priced at 279,800 RMB and 299,800 RMB respectively; the seven-seat model starts at 271,800 RMB [2] - The official pricing is approximately 14,100 RMB lower than the pre-sale price announced on July 10, indicating a strategic pricing adjustment [2] - The L90 model includes high-end features such as an 85kWh battery, L2-level intelligent driving assistance system, and Orin-X chip, with promotional offers to encourage purchases [2] - The management's pricing strategy reflects a strong commitment to achieving sales targets, with expectations of monthly sales exceeding the market forecast of 5,000 units [2] - The success of the L90 model is anticipated to pave the way for the upcoming L80 model, contributing to a turnaround in NIO's sales performance [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 交銀國際控股有限公司 | | | 呈交日期: | 2025年8月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 第 2 頁 共 10 頁 v 1.1.1 FF301 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） 不適用 第 3 頁 共 10 頁 v 1.1.1 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03329 | 說明 | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | ...

Core Viewpoint - The Federal Reserve decided to maintain the federal funds rate target range at 4.25% to 4.5% during the July FOMC meeting, marking the fifth consecutive meeting without a rate cut, aligning with market expectations [1] Group 1: Federal Reserve Decisions - The Fed's decision to pause rate cuts reflects a cautious approach, as the impact of tariffs has a lagging effect that has not yet fully manifested [1] - The probability of a rate cut in September decreased from approximately 65% before the meeting to around 45% afterward, indicating a shift in market sentiment [1] - The Fed is expected to wait for two complete rounds of employment and inflation data before making further decisions, particularly regarding the transmission of commodity price pressures [1] Group 2: Market Implications - The outlook for rate cuts in 2023 has moderated, with expectations for 1-2 rate cuts by the end of 2025, and the first potential cut could occur in the fourth quarter [1] - Concerns about dollar credit risk and capital market performance may limit political pressures on the Fed, including potential calls for tariff adjustments or dismissing Fed Chair Powell [1]

交银国际发布研报称，维持新东方-S(09901)港股目标价46港元及"买入"评级。该行下调2026/2027财年 公司收入约3%，预计收入增速10%/14%，下调营运利润约17%，预计营运利润率10.2%/10.5%，较2025 财年微增。仍看好K12教培相关业务需求及增长前景。 留学相关业务影响仍持续，管理阶层指引2026财年集团收入增加5-10%，对比市场预期的12%，主要调 整仍在于出国相关业务增速预期调整至下降5%，K12相关业务增长率维持市场预期(19%)。公司加速成 本优化，致力于全年实现营运利润率稳定或微增目标。 该行称，第1季度指引低于预期主要受到季节性因素影响，第2-4季度增速将恢复。调整估值方法至 SOTP，分别给予2026财年K12业务15倍/留学业务8倍市盈率，对应利润增速分+22%/-10%。交银国际 指，2025财年4季度收入同比增9.4%，超该行/机构预期2%/5%。不含东方甄选(01797)，教育/文旅收入 同比增19%，教育营运利润率6.5%，较去年同期提升410个基点，得益于有效的降本增效措施。 ...

Core Viewpoint - The report from CMB International maintains a target price of HKD 46 for New Oriental-S (09901) and a "Buy" rating, while adjusting revenue and operating profit forecasts for the fiscal years 2026 and 2027 downward by approximately 3% and 17% respectively [1] Group 1: Financial Projections - Revenue growth is expected at 10% and 14% for fiscal years 2026 and 2027 respectively, with an operating profit margin projected at 10.2% and 10.5%, showing a slight increase compared to fiscal year 2025 [1] - The fourth quarter of fiscal year 2025 saw a revenue increase of 9.4% year-on-year, surpassing the expectations of CMB International and other institutions, which were 2% and 5% respectively [1] - Excluding Dongfang Zhenxuan (01797), education and cultural tourism revenue increased by 19% year-on-year, with an education operating profit margin of 6.5%, up 410 basis points from the same period last year due to effective cost reduction and efficiency improvement measures [1] Group 2: Business Segments and Market Outlook - The guidance for the first quarter was below expectations primarily due to seasonal factors, but growth is expected to recover in the second to fourth quarters [1] - The management's guidance for fiscal year 2026 indicates a group revenue increase of 5-10%, compared to the market expectation of 12%, with the main adjustment being a downward revision of the growth forecast for overseas-related business to a decline of 5% [1] - The growth rate for K12-related business is maintained at the market expectation of 19% [1] Group 3: Valuation Methodology - CMB International has adjusted its valuation method to SOTP, assigning a price-to-earnings ratio of 15 times for K12 business and 8 times for study abroad business for fiscal year 2026, corresponding to profit growth rates of +22% and -10% respectively [1] - The company is accelerating cost optimization efforts, aiming to achieve stable or slightly increased operating profit margins for the entire year [1]

Core Viewpoint - The stock of China International Capital Corporation (CICC) has shown significant growth, with a cumulative increase of 110.71% over the past month and 87.3% year-to-date, outperforming the Hang Seng Index by 25.27% [2] Group 1: Financial Performance - As of December 31, 2024, CICC reported total operating revenue of 359 million yuan, a year-on-year decrease of 36.8% [2] - The company recorded a net loss attributable to shareholders of 1.14 billion yuan, an increase of 16.21% year-on-year [2] - The asset-liability ratio stands at 93.92% [2] Group 2: Market Position and Valuation - Currently, there are no institutional investment ratings for CICC [3] - The average price-to-earnings (P/E) ratio for the financial industry (TTM) is 16.25 times, with CICC's P/E ratio at -1.31 times, ranking 153rd in the industry [3] - Other financial companies have P/E ratios ranging from 2.63 times to 4.8 times [3] Group 3: Company Overview - CICC, established in 1998, is one of the earliest licensed securities firms in Hong Kong with a Chinese background [4] - The company has evolved into a large securities firm specializing in brokerage, margin financing, corporate financing, underwriting, investment, loans, asset management, and advisory services [4][5] - CICC aims to leverage cross-border business opportunities and provide comprehensive financial services to create greater value for clients and shareholders [4]

Group 1 - The Hang Seng Index closed down by 0.08% while the Hang Seng Tech Index increased by 0.56% [1] - The Hong Kong Tech ETF (159751) rose by 1.22%, whereas the Hang Seng Hong Kong Stock Connect ETF (159318) fell by 0.30% [1] - Pop Mart experienced a decline of 0.87% after a recovery attempt [1] Group 2 - China International Capital Corporation (CICC) saw a significant drop of over 11% [1]

Group 1 - The core viewpoint of the report is that the target price for Kangfang Biotech (09926) has been raised by 21.7%, from HKD 115 to HKD 140, while maintaining a "Buy" rating [1] - Key short-term catalysts include: 1) Overseas application and complete data publication of the HARMONi study; 2) Publication of the AK112-306 study at ESMO 2025; 3) Results of multiple product/indication health insurance negotiations in Q4 2025; 4) Progress of more early-stage projects like ADC [1] - The company is optimistic about the overseas approval prospects of Ivosidenib, with a clearer path for it to become a new generation I/O cornerstone drug, replacing PD-(L)1 single-target therapies [1] Group 2 - Cardunili's overseas development has initiated liver cancer research, with the recent approval of its third indication for first-line cervical cancer in the general population, and potential participation in health insurance negotiations later this year [2] - The company is starting a Phase II study of Cardunili in combination with Lenvatinib overseas, with expectations of seeing more assets registered and listed in the next 2-3 years [2] - The differentiated ADC development strategy is progressing well, with the first ADC (HER3) entering clinical trials and the first bispecific ADC AK146D1 completing its first patient enrollment [2]